Hormone Replacement Therapy Market Analysis Report By Product, By Route Of Administration, By Type Of Disease, By Region And Segment Forecasts From 2020 To 2027

Synopsis

The global hormone replacement therapy market was prized by USD 21.8 billion in 2019. It is estimated to witness 7.7% CAGR from 2020 to 2027.

Drivers

The complaints of hormonal discrepancy, which includes menopause, are the most important factors propelling the market for hormone replacement therapy. The female body experiences a number of categories of hormonal alterations. Hormone stages get distorted amid increasing age, causing a variety of diseases as well as the complaints.

As a result of hormonal imbalance, specific problems are surfaced such as muscle loss, weaken memory, increase in weight, low down libido, and fatigue. The most important source of populace affecting the market is menopausal females. The standard opening period of menopause between women is approximately 45 to 50 years. The hormonal stages of estrogen and progesterone significantly reduce in menopausal women.

As soon as the hormone stages within the body goes down as contrast to the normal stages, necessary for the appropriate working of the body, hormone replacement is suggested, which is intended for restocking the hormones, within the human body.

The rising figure of women, those are on the point of attaining menopause, together with the broadening of the menopausal gap to 40 to 55 years, is estimated to direct the market for hormone replacement therapy (HRT).

Route of Administration Insight

Based on the route of administration, the hormone replacement therapy market is subdivided into oral tablets, parenteral, transdermal patches, plus others. On the basis of revenue share, the parenteral section led the general market, in 2019. The oral route of administration is frequently chosen for testosterone medicines. The other section comprises the products like vaginal tablets, implants, vaginal creams, and vaginal rings.

Product Insight

The product division contains treatments for thyroid hormones, testosterone, estrogen, and human growth hormone. The estrogen hormone replacement therapy section held the maximum revenue share and led the general market, in 2019.

Estrogen replacement therapy is utilized in women throughout hysterectomy or post-menopause and assists them to uphold the hormonal equilibrium. Estrogen sourced products are reported generating the major amount of prescriptions, therefore creating it the leading section.

On account of the growing occurrences of development insufficiency, mainly in newborns, human growth hormone therapy is likely to observe the highest expansion, during the forecast period. In accordance with an investigation, conducted by the World Health Organization (WHO), almost 15.0 million infants are born untimely and roughly 85.0% of these babies are not completely developed. The hormone therapy is offered for the situations for example pituitary tumors, and short bowel syndrome, in adults. The major companies engaged in the improvement of medicines utilized in these treatments are Novartis (Sandoz), Pfizer, Novo Nordisk, Merck, Eli Lilly, and Roche.

Type of Disease Insight

In the type of disease section, menopause is anticipated to be the highest rising section, during the forecast period. In line with the information given by the American Congress of Obstetricians and Gynecologists, every day roughly 6,000 women arrive at menopause.

The existence of diverse generic as well as branded medicines along with rising alertness between women is expected to be the most important drivers. Increasing figure of women, those are on the verge of attain menopause as well as enlarging menopausal gap from 40 to 55 years is impelling the enlargement of the section.

Regional Insight

In terms of revenue share, North America led the general global hormone replacement therapy market, in 2019. Increasing targeted populace within North America, advancement in the drug deliverance systems, and improvement of latest formulations, are the factors projected to retain its domination, during the forecast period. As per the NIH statement at least once the half population of the entire postmenopausal state women have utilized hormone replacement therapy.

In contrast, Asia Pacific is projected to observe the highest development, during the forecast period. Increasing concentration of healthcare suppliers on the abolition of hormonal dearth, and rising stages of alertness are anticipated to increase the enlargement of the provincial market.

Companies

The global market for hormone replacement therapy is differentiating through the rising amount of partnerships, approvals, enlargement by means of acquisitions.

Some of the companies for hormone replacement therapy market are:

    • Eli Lilly
    • Novo Nordisk
    • Mylan Laboratories
    • Novartis
    • Genentech
    • Bayer Healthcare
    • Merck and Co.
    • Pfizer, Inc.
    • Abbott Laboratories

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Million Insights has segmented the global hormone replacement therapy market report based on product, route of administration, type of disease, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2027)
    • Estrogen Hormone Replacement Therapy
    • Human Growth Hormone Replacement Therapy
    • Thyroid Hormone Replacement Therapy
    • Testosterone Hormone Replacement Therapy

• Route of Administration Outlook (Revenue, USD Million, 2016 - 2027)
    • Oral
    • Parenteral
    • Transdermal
    • Others

• Type of Disease Outlook (Revenue, USD Million, 2016 - 2027)
    • Menopause
    • Hypothyroidism
    • Male Hypogonadism
    • Growth Hormone Deficiency
    • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2027)
    • North America
        • U.S.
        • Canada
    • Europe
        • U.K.
        • Germany
    • Asia Pacific
        • Japan
        • China
    • Latin America
        • Brazil
        • Mexico
    • Middle East & Africa
        • South Africa
        • Saudi Arabia